drugset / Trial / NCT06027073
Biologics and Sublingual Immunotherapy
Phase 4
Not yet recruiting
150 enrolled
Medical University of Silesia
Centrum Medyczne Andrzej Bożek · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Most current studies involve using a biological drug to increase the safety of allergen immunotherapy (AIT) especially in the treatment of food allergies, to avoid the risk of anaphylaxis. However, adding Xolair® to AIT may improve the therapy's effectiveness. There are still few observations on this topic, especially in patients with house dust mite (HDM)-driven asthma.
Timeline
- Start
- 2024-05-01
- Primary completion
- 2026-10-01
- Completion
- 2028-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Omalizumab | Monoclonal antibody | — | — |